Motus GI Stock Surges On FDA Approval For Next-Gen Pure-Vu EVS System


The FDA has granted 510(k) clearance to Motus GI Holdings Inc's MOTS upgraded Pure-Vu EVS System. 

  • The new Pure-Vu EVS System is intended to improve the speed of set-up, enhance navigation capabilities in tortuous anatomy, build upon the Pure-Vu system's cleansing capabilities, and enable physicians to rapidly overcome the challenges of poorly prepared colons during a colonoscopy.
  • The Pure-Vu platform facilitates the cleaning of a poorly prepared colon to improve visualization during the colonoscopy procedure. 
  • The platform integrates with standard and slim colonoscopes and preserves established procedural workflow by irrigating the colon and evacuating debris to provide a better-quality exam. 
  • The new Pure-Vu EVS is designed to offer significant usability advancements over the currently marketed device, including enhanced physician navigation and control, on-demand bedside loading, expanded cleansing capacity, and a smaller workstation footprint. 
  • The commercial launch of the Pure-Vu EVS in Q1 of 2022.
  • Price Action: MOTS shares are up 37.60% at $0.58 during the premarket session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: NewsPenny StocksHealth CareFDAMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!